Leukoplakia

01Pathophysiology

Leukoplakia is fundamentally a clinical diagnosis of exclusion. The term describes a white plaque on the oral mucosa that cannot be characterized as any other definable lesion. It is not a histopathologic diagnosis by itself; rather, the histopathologic findings range from benign hyperkeratosis to severe dysplasia or even carcinoma in situ.

The pathogenesis begins with chronic exposure to irritants or carcinogens, most commonly from tobacco. Chemical compounds in tobacco smoke and smokeless tobacco products cause repeated injury to the oral epithelial cells. In response, the basal layer of the epithelium undergoes increased proliferation, and the superficial layers accumulate excess keratin. This process, called hyperkeratosis, produces the characteristic white appearance. The white color arises because the thickened keratin layer absorbs water from saliva and appears opaque, similar to how waterlogged skin on your fingers turns white.

Over time, continued carcinogen exposure can drive genetic mutations in the epithelial cells, leading to epithelial dysplasia. Dysplasia represents disordered cellular growth with features such as increased nuclear-to-cytoplasmic ratio, loss of normal maturation pattern, increased mitotic figures, and basilar hyperplasia. The critical clinical concern is that dysplasia is the bridge between a benign reactive process and oral squamous cell carcinoma (OSCC). The overall rate of malignant transformation ranges from approximately 1% to 9%, though certain subtypes carry a much higher risk.

The location of the lesion also carries prognostic significance. Leukoplakia on the floor of the mouth, the ventrolateral tongue, and the soft palate has a higher rate of dysplasia and subsequent malignant transformation compared to lesions on the buccal mucosa or hard palate. This is because these high-risk sites have thinner, non-keratinized epithelium that is more permeable to carcinogens.

Erythroplakia (a red mucosal patch) and erythroleukoplakia (a mixed red and white patch) carry a significantly higher risk of harboring dysplasia or carcinoma at the time of biopsy than homogeneous leukoplakia. This is an important concept on exams: if a vignette describes a red patch rather than a white one, the premalignant risk is actually higher.

02Classification and Clinical Manifestation

The WHO definition (updated) classifies leukoplakia as a "white plaque of questionable risk, having excluded other known diseases or disorders that carry no increased risk for cancer." This means you must first rule out other causes of oral white patches before labeling a lesion as leukoplakia.

03Diagnostic Workup

The workup begins with a thorough clinical examination. The examiner should document the location, size, color, surface texture, and borders of the lesion. A critical first maneuver is attempting to wipe the lesion off with gauze. If it can be removed, the diagnosis shifts toward oral candidiasis (thrush), not leukoplakia. This is one of the most commonly tested distinguishing features.

If the white patch cannot be removed, the clinician must exclude other identifiable white lesions before calling it leukoplakia. Conditions to rule out include lichen planus (look for Wickham striae and bilateral reticular patterns), frictional keratosis (from a clear source of mechanical irritation that resolves when the source is removed), white sponge nevus (bilateral, familial, present since childhood), and leukoedema (bilateral, grayish-white, disappears on stretching the mucosa).

Once other causes are excluded, the next best step is incisional biopsy. This is non-negotiable. A clinical diagnosis alone is insufficient because the critical question is whether dysplasia is present, and that can only be answered histologically. If the lesion is non-homogeneous, the biopsy should target the most clinically suspicious area (typically the reddish or nodular component). For large lesions, multiple biopsies from different sites may be necessary.

Histopathologic findings range along a spectrum:

Adjunctive tools such as toluidine blue vital staining or autofluorescence visualization can help identify the most suspicious areas to biopsy but do not replace tissue diagnosis.

04Management and Treatment

Step 1: Risk factor elimination. This is universally the first intervention regardless of biopsy results. Tobacco cessation is the single most important modifiable risk factor. In patients whose leukoplakia is attributed to chronic mechanical irritation (e.g., a rough dental restoration), the source of irritation should be corrected, and the lesion should be re-evaluated after 2 to 4 weeks. If the lesion resolves, it was likely frictional keratosis and not true leukoplakia. If it persists, biopsy is required.

Step 2: Biopsy-guided decision-making. The management strategy depends entirely on the histologic grade.

For lesions without dysplasia, the standard approach is watchful waiting with clinical follow-up every 6 to 12 months. The patient should be educated about warning signs such as growth, color change (especially the development of red areas), induration, ulceration, or pain.

For mild dysplasia, there is debate regarding whether to excise or observe. In practice, excision is recommended when the lesion is in a high-risk location or when the patient has additional risk factors. Surveillance alone is acceptable for small lesions in low-risk sites, provided the patient is compliant with follow-up.

For moderate to severe dysplasia, surgical excision is the standard of care. The ${\text{CO}}_2\backslash text\{CO\}\_2$ laser is commonly used because it provides precise ablation with good hemostasis and reduced morbidity. Conventional cold-knife excision is an alternative and has the advantage of providing intact surgical margins for pathologic evaluation. Cryotherapy is a less commonly used option.

Step 3: Post-treatment surveillance. Recurrence rates are notable, ranging from 10% to 35% depending on the type and treatment modality. Patients should be followed every 3 to 6 months after excision with clinical examination and repeat biopsy of any new or recurrent lesion.

Chemoprevention: Retinoids (systemic vitamin A analogues such as isotretinoin) have been studied for chemoprevention of oral leukoplakia. While some trials have shown initial regression, lesions frequently recur after discontinuation of the drug, and side effects (teratogenicity, hepatotoxicity, mucocutaneous dryness) limit long-term use. Currently, there is no pharmacologic agent with proven long-term efficacy for preventing malignant transformation. Beta-carotene and lycopene have been explored in smaller studies with variable results and are not part of standard guidelines.

05Differential Diagnosis and Distractors

06Traps and High-Yield Pearls

The most common way students lose points on leukoplakia questions involves confusing it with oral candidiasis. Both present as white lesions in the mouth, but the defining clinical maneuver is whether the lesion can be wiped away. If the vignette says "white patch that cannot be scraped off," the answer is leukoplakia (or one of its differentials). If the patch "can be scraped off revealing an erythematous base," it is candidiasis. Test-writers rely heavily on this single detail.

A second frequent trap is confusing leukoplakia with oral hairy leukoplakia. Despite sharing the word "leukoplakia" in their names, these are entirely different entities. Oral hairy leukoplakia is caused by EBV, is found on the lateral borders of the tongue, is a marker for HIV/immunosuppression, and has zero malignant potential. True leukoplakia is a premalignant disorder. If the vignette mentions an HIV-positive patient with white patches on the lateral tongue, think oral hairy leukoplakia, not leukoplakia.

Another tested concept is the comparison between leukoplakia and erythroplakia. Students often assume that a white patch is more dangerous than a red one, but the opposite is true. Erythroplakia has a significantly higher rate of dysplasia and carcinoma at the time of diagnosis. If a vignette presents a red velvety patch in the oral cavity, the urgency for biopsy and the suspicion for malignancy should be even higher than for a white patch.

Finally, remember that biopsy is always required. A clinical diagnosis of leukoplakia is incomplete without histopathology. The question being tested is whether you understand that the appearance alone cannot determine the presence or grade of dysplasia, and therefore cannot guide treatment. The next best step for a persistent, non-removable white patch after ruling out other causes is always an incisional biopsy.

The core competency being assessed on this topic is the ability to (1) recognize a premalignant oral lesion from a vignette, (2) correctly sequence the diagnostic workup with biopsy as the definitive step, (3) distinguish leukoplakia from its closest mimics using one or two discriminating details, and (4) understand the spectrum from benign hyperkeratosis through dysplasia to invasive carcinoma.